The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

The Durham ID building in downtown Durham, NC holds the North Carolina office of Tune Therapeutics, a growing biotech startup moving into trials. Brian Gordon Launched from a Duke University lab ...

A Durham biotech firm founded on technology ... Why it matters: The fundraising round by Tune Therapeutics is one of the largest in the Triangle in recent months and will give the company runway ...

(Tune Photos) Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.

In less than 36 hours between the evening of Jan. 12 and the morning of Jan. 14, three local life science companies raised a ...

has now been approved for clinical trials in both Hong Kong and New Zealand DURHAM, N.C. & SEATTLE, January 07, 2025--(BUSINESS WIRE)--Leading epigenetic therapy company Tune Therapeutics ...

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced ... offices in Seattle and at the downtown Durham ID building. Series A and B are the two ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.